
Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
2
The Ongoing Debate Over E-Cigarettes and Public Health
3
FDA Approves CytoCell CDx for Revumenib in KMT2A-Mutant Acute Leukemia
4
Respiratory Health Risks Linked to Chemical Cleaners and Biomass Fuel in Homes
5